Despite the availability of medicines with proven efficacy, many patients use complementary or alternative medicines (CAMs) to manage atopic eczema (AE). Due to the lack of objective information on topical CAMs, this systematic review evaluates the current evidence for the efficacy and safety of topical herbal preparations in AE. Using Cochrane systematic review methodology, PubMed, the Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (via EBSCO), MEDLINE (via EBSCO), Proquest Health and Medical Complete, GREAT and CAM-QUEST were searched from inception until June 2014. Bibliographies of retrieved studies were hand searched for further relevant trials. All controlled clinical trials of topical herbal medicines for AE in humans of any age were included regardless of the control intervention or randomization. Only English-language publications were considered. Eight studies met the inclusion criteria. Seven investigated extracts of single plants and one an extract from multiple plants. Only two studies that showed a positive effect were considered to have a low risk of bias across all domains (those of liquorice gel and Hypericum perforatum). In these two, the test product was reported to be superior to placebo. Despite variations in diagnostic criteria and lack of validated tools for outcome assessments in one of these, the promising results may warrant continued research in better-designed studies. No meta-analysis was performed due to heterogeneity in all studies. There is currently insufficient evidence of efficacy for any topical herbal extract in AE. Many studies had methodological flaws and even those showing efficacy were single trials with small patient cohorts.
Atopic eczema (AE) is a chronic, relapsing and frustrating condition, with marked effects on quality of life (QoL). Despite the availability of medicines with proven efficacy, many patients resort to complementary or alternative medicines (CAMs) to manage flare-ups. [1] [2] [3] Many of these CAMs have shown conflicting evidence of efficacy, and hence systematic reviews have sought to provide clarity on their role for AE. Previous systematic reviews have focused on oral CAMs, [4] [5] [6] [7] [8] and an overview of these concluded that there was currently no evidence of efficacy. 9 Topical corticosteroids remain the mainstay of treatment for AE. Many patients are concerned about their long-term safety and seek evidence-based safer alternatives. [10] [11] [12] Many topical herbal preparations have been tested for AE, but few in controlled clinical trials. [13] [14] [15] [16] [17] [18] [19] [20] We have found no systematic reviews of these trials, although systematic reviews of topical herbal extracts have been published for other chronic skin conditions, such as psoriasis. [21] [22] [23] In 2014, a Cochrane protocol was registered with the aim to review all randomized controlled trials (RCTs) of several forms of CAMs (including phytotherapy) and complementary techniques (including acupuncture). 24 No review based on this protocol has yet been published. Our systematic review focuses specifically on controlled trials of topical herbal preparations (whether randomized or not), and on evidence of efficacy and safety. The overall aims are to provide clarity to prescribers and patients, and to identify opportunities for future research.
Methodology Data sources
This systematic review was conducted independently with reference to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (no registered protocol). 25 The electronic databases searched from inception until June 2014 were PubMed, the Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (via EBSCO), MEDLINE (via EBSCO), Proquest Health and Medical Complete. Subsequent searches were conducted in two additional databases (CAM-QUEST and GREAT). Bibliographies of retrieved studies were hand searched for other relevant trials. Search terms were 'atopic eczema/atopic dermatitis' together with 'topical herbal', 'topical application', 'topical administration', 'plant extract', 'natural', 'cream', 'ointment' and their synonyms. These were adjusted according to suitability for each database. The corresponding author may be contacted for a list of the search terms per database. The search terms and strategy are summarized in Appendix S1 (see Supporting Information).
Inclusion and exclusion criteria
All controlled clinical trials published in English that tested a topical herbal medicine for AE in human patients of any age were included, regardless of the control intervention or randomization.
Topical herbal medicines were defined as those containing extracts of multiple or single plants. These could include nonherbal ingredients used in the extraction process or in preparation of the test or vehicle. Preparations described as homeopathic were not excluded. Any preparations incorporating or combined with an active pharmaceutical ingredient, other bioactive ingredients, vitamins or minerals were excluded. Topical Chinese herbal medicines were also excluded, as a recent systematic review dealing specifically with these was published in 2014. 26 All patients had to be clinically diagnosed with AE. Studies on other types of eczema (e.g. hand eczema) and where the type of eczema was not clearly classified (e.g. chronic eczema) were excluded. Case reports, case series and clinical trials not conducted within a controlled environment were also excluded.
Data extraction and analysis
Titles and abstracts of the initial search were scrutinized by two reviewers (Y.T. and A.M.) and a selection of full texts was made. Discrepancies were clarified by two independent reviewers (J.B. and A.G.).
Data from included trials were extracted by one reviewer (Y.T.) and checked by the others. Study authors were contacted where clarity was required. Details of the extracted data and study descriptions are included in Table 1 . The risk of bias in each study was assessed by three independent reviewers (Y.T., A.M. and A.G.) according to the Cochrane domainbased evaluation. 27 Table 2 includes this assessment.
Results

Literature search
The initial searches yielded 3813 potential studies. After removing duplicates, 2451 potential papers remained. Considering the inclusion and exclusion criteria, the full texts of 41 publications and three studies from reference lists were retrieved. Eight publications were finally selected. Subsequent searches of additional databases did not yield any studies that met the inclusion criteria. Figure 1 shows the results of the selection process. All eight studies were RCTs conducted between 1990 and 2011. Four were conducted in Germany, 15, 16, 18, 19 with the others in Spain, 14 the U.K., 17 Iran 13 and the Philippines. 20 Five were intraindividual paired left-right comparison trials. [15] [16] [17] [18] [19] Participants ranged in age from 4 months to 65 years. The largest trial included 88 patients 19 and the smallest 12 patients. 17 Treatment duration ranged from 4 weeks 15, 19, 20 to 2 weeks. 13, [16] [17] [18] The severity of AE varied.
Three studies included patients with mild-to-moderate AE, 13, 17, 19 one with moderate AE 18 and another with moderately severe AE. 16 One study included patients with low-tohigh/moderate objective Scoring Atopic Dermatitis (SCORAD) scores, implying a varied degree of AE severity. 20 One study included patients with SCORAD < 80 and another, 15-60, hence there was a wide variation in severity. 14, 15 Primary outcome measures were a modified SCORAD using a four-point scale assessment in five studies, 13, 15, 16, 18, 19 SCORAD in one study, 14 objective SCORAD in one 20 and a 10-point self-assessment of symptoms in another. 17 Staphylococcus aureus colonization was measured in two studies 15, 20 and tolerability was assessed secondarily in four studies. 15, 16, 18, 19 Only one study assessed health-related QoL.
14 Four studies compared a topical plant extract with a topical placebo. 13, 15, 17, 19 Two trials were two-arm parallel studies (comparison with placebo and hydrocortisone 0Á5%). 16, 18 In another two, the test treatment was compared with a topical active control: hydrocortisone butyrate propionate 14 or virgin olive oil. 20 Seven studies investigated single-plant extracts, and one studied extracts from multiple plants. 19 These were sunflower oleodistillate, Hypericum perforatum L (St John's wort), Hamamelis virginiana distillate, evening primrose oil (EPO), chamomile, Glycyrrhiza glabra L (liquorice gel), virgin coconut oil (VCO) and an ointment containing extracts of Mahonia aquifolium, Viola tricolor and Centella asiatica.
Risk-of-bias assessment
The judgement of risk of bias per domain is summarized in Table 2 and depicted in Figure 2 . Selection bias in terms of sequence generation was unclear in all studies. Only one reported randomization 14 and none stated any method of sequence generation. All studies stated that participants were randomly allocated into treatment groups, hence allocation concealment was considered to be low risk in all but one study. 14 Although two did not provide any detail on the method of randomization, they were classified as low risk. 15, 17 Four studies demonstrated a high risk of performance bias, 14, 16, 18, 20 with two also having a high risk of detection bias. 14, 18 In the study of Patzelt-Wenczler and Ponce-Poschl No addiƟonal studies that meet the inclusion criteria to its distinct colour and smell. 18 The study of De Belilovsky et al. (2% sunflower oleodistillate) was observer blinded.
14 Participants were unblinded and were given different instructions on application of the creams. Although they reported that this was unlikely to influence the outcome, the study was classified as having high risk of performance bias. 14 Unblinding of parents and carers may affect adherence, especially if the corticosteroid is known. Also, it was unclear how the commercial test and control products were packaged and supplied to maintain blinding. These factors generated a study with high risk of detection bias. In the study of Verallo-Rowell et al. (VCO), the creams were distinguishable by scent and appearance prior to application. 20 Despite the authors' claim that this was unlikely to have influenced the results, we considered the performance bias as being high. In the study of Korting et al. (Hamamelis distillate), the treatment and control creams were dispensed in neutral, coded 50-g tubes; however, no mention was made of the similarity of texture, colour or smell, thus the double blinding may have been ineffective. 16 Also, patients had to be actively motivated to complete the trial as they felt uncomfortable with the medication due to delayed onset of desired effect and having received potent glucocorticoids previously. This study was thus regarded as having a high risk of performance bias. Two studies had incomplete outcome data and were considered to have a high risk of attrition bias. 16, 19 Korting et al.
(Hamamelis distillate) had seven dropouts, in whom analysis was performed on intention-to-treat numbers and the last value obtained served for analysis. 16 These values were not mentioned, thus the missing data could have resulted in inaccuracies. Conflicting figures exist in this study, as an initial report of seven dropouts was inconsistent with another statement that four patients withdrew (three test and one control).
Another discrepancy was a statement that 65 patients completed the trial, but a later statement said that 61 complied with the full trial protocol. Despite the poor-quality reporting, the results were not in favour of the test product. 16 Approximately 20% of the sample dropped out in the study of Kl€ ovekorn et al. (multiple-plant extracts) due to lack of efficacy. 19 Analyses were performed on the intention-to-treat data. The missing data could have led to inaccurate results. Attrition bias in the other studies was low, due to no dropouts, 13, 14, 20 small dropout numbers 15, 17, 18 or clear reasons for dropouts. [15] [16] [17] [18] All eight studies were considered to be at low risk for selective reporting, as all outcomes assessed as part of the trial objectives stated in the paper were reported in the results. One study did not report on additional symptoms investigated as part of the outcomes; however, the risk was low, as all major symptoms were reported. 18 Other potential sources of bias exist in two studies. 14, 17 In
De Belilovsky et al. (2% sunflower oleodistillate), all children were given Stelatopia â milky bath oil for daily use. Compliance is uncertain and it is possible that its regular use could improve symptoms and bias the results. Also, no mention was made of washout periods with previously used systemic corticosteroids, antibiotics or immunosuppressants. 14 In Anstey et al. (EPO), no restrictions were given with any topicals used on other areas of the body. 17 The risk was considered high, as systemic absorption of these could potentially produce inaccurate outcomes. Only three studies measured compliance. Two collected and weighed tubes 14, 15 and one collected tubes and documented application frequencies. 19 Follow-up was mentioned in only one study, which ceased after 2 weeks. 13 Diagnostic criteria varied among studies. 13, 14, 18 Three reported the use of the Hanifin and Rajka criteria. 16, 17, 19, 28 One used the modified Hanifin and Rajka criteria, 20 and another used the criteria recommended by the European Task Force on Atopic Dermatitis (1993). 15, 29 Of five studies that used a four-point scale to measure outcomes, 13, 15, 16, 18, 19 only four used the same scale, with erythema being the only common symptom assessed. Three were placebo controlled and two included two comparator arms (placebo and hydrocortisone 0Á5% cream). Four were halfsided intraindividual comparisons. Due to these differences, a meta-analysis was not considered feasible. Six studies reported on adverse events, [14] [15] [16] [17] [18] [19] of which three reported that there were none, 14, 17, 19 and the others reported that none was serious. 
Description of studies
Topical single-plant extracts compared with placebo (n = 4)
Published in 2003, a randomized, placebo-controlled, doubleblind trial was conducted by Schempp et al. 15 In this intraindividual bilateral comparison, the effects of St John's wort cream, containing hyperforin (a major constituent of H. perforatum) on AE intensity were compared with placebo using a modified SCORAD of objective variables. Secondary outcomes were S. aureus colonization and tolerability. The investigators found that St John's wort cream significantly improved the intensity of AE and reduced S. aureus skin colonization compared with placebo. Tolerability was good, with only a few nonserious adverse effects reported.
15
A randomized, double-blind, placebo-controlled, intraindividual bilateral comparison trial with topical EPO was published in 1990. 17 In this pilot study, the effects of topical EPO on eczema severity were assessed by patients and physicians using a 10-point scale. A statistically significant difference only in patient scores (not doctor's) was noted, concluding that despite uncertainty of emollient or anti-inflammatory effects, topical EPO has the potential to improve eczema. 17 No published main study following this pilot was found. Published in 2003, Saeedi et al. investigated the effect of liquorice gel 1% and 2% (extracted from G. glabra L roots). 13 This was a randomized, double-blind, placebo-controlled three-arm trial. Symptoms were assessed using a four-point scale. Itching, oedema, erythema and scaling were reduced more effectively with liquorice 2% gel compared with 1%. Both were more effective than placebo. The investigators concluded that liquorice 2% extract could be considered in AE management. 13 Topical multiple-plant extracts compared with placebo (n = 1)
In 2007, Kl€ ovekorn et al. compared an ointment containing extracts of M. aquifolium, V. tricolor and C. asiatica with placebo. 19 This was a bilateral intraindividual comparison. Efficacy was based on a modified SCORAD four-point-scale investigator assessment of objective parameters. Subjective variables were assessed by the patient. A global assessment of effectiveness and tolerability was also assessed. The investigators concluded that this extract was not superior to placebo. Considering the study was conducted over a period of varying climatic conditions, a subanalysis over similar climatic conditions concluded that the cream might be effective.
19
Topical single-plant extracts compared with topical corticosteroids (n = 3)
Three studies compared topicals from single-plant extracts with topical corticosteroids. 14, 16, 18 Two were three-arm studies (comparison with corticosteroid and placebo). 16, 18 Sunflower oleodistillate 2% ( 18 This study was only partially double blinded because the colour and smell of chamomile extract easily distinguished it from placebo and corticosteroid. A four-point assessment of symptoms and investigator global assessment were the main outcomes. A marked superiority of the chamomile extract over hydrocortisone 0Á5% and a marginal superiority over placebo on assessment of pruritus, erythema and desquamation were reported. No reports were given regarding the other symptoms assessed.
18
Topical single-plant extracts compared with other pharmaceuticals (n = 1)
In a 2008 double-blinded RCT by Verallo-Rowell et al., the effects of VCO on objective symptoms of SCORAD and S. aureus colonization were compared against virgin olive oil. 20 Both oils improved severity scores, but improvement was better with VCO. VCO was also superior in reducing S. aureus colonization. The investigators concluded that VCO and its key ingredient monolaurin may be useful in the proactive treatment of AE.
Discussion
This systematic review reports on trials conducted over the past 25 years. Despite this lengthy period, evidence regarding the use of topical plant extracts still remains unclear. Objective information rather than complete rejection is essential for any clinician treating patients who may be using or wanting to consider CAMs. Of eight RCTs included in this review, two reported no efficacy. 16, 19 The Korting et al. study (Hamamelis distillate) had a high risk of performance bias, possibly leading to inaccurate results. 16 The Kl€ ovekorn et al. study (multiple-plant extracts)
reported a high dropout rate due to lack of efficacy and thus had a high risk of attrition bias. 19 The intention-to-treat analysis revealed negative results. It is therefore unlikely that a better-designed study would show any positive effect. Six studies reported that the extracts tested were effective. [13] [14] [15] 17, 18, 20 However, there were no common data that were suitable for a meta-analysis. Of these, the Patzelt-Wenczler and Ponce-Poschl study (Kamillosan â ), which reported that chamomile extract was mildly superior to topical corticosteroid, was considered to be at high risk of performance and detection bias, lending itself towards a positive effect. 18 No statistical analysis or follow-up was reported. Considering this, the claim of superiority over a topical corticosteroid cannot be supported by the data in this trial. Following this 2000 publication, we have found no other trials with a chamomile extract for AE. Another better-designed study ensuring complete blinding would be useful. The De Belilovsky et al. study (sunflower 2% oleodistillate) had selection, performance and detection biases. 14 Other potential biases were uncertainty of washout periods with prior medicines and the concurrent use of a milky bath oil, which may have led to a false positive result. Results of comparability of the test cream with a topical corticosteroid and its consideration as first-line treatment for mild-to-moderate AE were reported in this 3-week observer-blinded trial. A longer trial, with double blinding, addressing the flaws in this study may be warranted. The Anstey et al. study (EPO) did not mention any validated instrument for assessing outcomes. A positive outcome was documented by patients only, with no statistical differences in doctors' assessments. 17 This study was considered to be at high risk of bias, as patients were allowed to use other topicals. A study excluding other medicines may be warranted. Although the study of Verallo-Rowell et al. (VCO) showed a positive effect, it had a high risk of detection bias. 20 The reduction in S. aureus colonization in this study is of limited clinical significance, as it was a cross-sectional study in a small number of patients (unbalanced at baseline), thus posing a high risk of a chance finding. Only two studies that showed superiority over placebo had low risk of bias across all domains. 13, 15 Despite variations in diagnostic criteria and a lack of validated tools for outcome assessments in one study, 13 its promising effect in the treatment of mild-to-moderate AE may warrant continued research using larger patient cohorts, in better-designed, longer-duration, possibly three-armed trials (with topical corticosteroids and placebo). Although a thorough literature search was conducted, some studies may have been missed. No information was obtained on unpublished studies. Despite every effort to use a wide array of databases, EMBASE and AMED were inaccessible. Studies published in languages other than English were not considered.
The heterogeneity among studies in terms of the tested product, age of participants, sample sizes, outcome measures and degree of eczema severity precluded the performance of a meta-analysis. The development of a minimum core outcome set to be used in future studies should be considered, as this would make it easier to compare results across trials and thus establish firm conclusions.
In conclusion, there is currently insufficient evidence of efficacy with any of the topical herbal extracts explored in this review. Many of the included studies were pilot studies and had methodological flaws, and even those that did show efficacy were single trials. Further trials with larger patient cohorts and longer follow-up to assess efficacy and record adverse effects may be warranted with those topical herbal extracts -H. perforatum extracts, liquorice gel 2% and EPOthat did show some promise.
